nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—BLK—systemic scleroderma	0.497	1	CbGaD
Vandetanib—ABCG2—Leflunomide—systemic scleroderma	0.0379	0.253	CbGbCtD
Vandetanib—ABCG2—Mycophenolate mofetil—systemic scleroderma	0.0234	0.156	CbGbCtD
Vandetanib—ALB—Captopril—systemic scleroderma	0.0205	0.137	CbGbCtD
Vandetanib—ALB—Mycophenolate mofetil—systemic scleroderma	0.0161	0.108	CbGbCtD
Vandetanib—ABCC1—Methotrexate—systemic scleroderma	0.014	0.0936	CbGbCtD
Vandetanib—ALB—Prednisone—systemic scleroderma	0.0129	0.0861	CbGbCtD
Vandetanib—ABCG2—Methotrexate—systemic scleroderma	0.00938	0.0627	CbGbCtD
Vandetanib—ALB—Methotrexate—systemic scleroderma	0.00647	0.0432	CbGbCtD
Vandetanib—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.00505	0.0338	CbGbCtD
Vandetanib—CYP3A4—Prednisone—systemic scleroderma	0.00404	0.027	CbGbCtD
Vandetanib—Afatinib—BLK—systemic scleroderma	0.00233	0.42	CrCbGaD
Vandetanib—KDR—umbilical vein—systemic scleroderma	0.00231	0.0307	CbGeAlD
Vandetanib—Bosutinib—CSK—systemic scleroderma	0.00221	0.398	CrCbGaD
Vandetanib—VEGFA—Enalapril—Captopril—systemic scleroderma	0.00173	0.633	CbGdCrCtD
Vandetanib—FLT4—endothelium—systemic scleroderma	0.00166	0.0222	CbGeAlD
Vandetanib—RIPK2—endothelium—systemic scleroderma	0.00165	0.0221	CbGeAlD
Vandetanib—TEK—artery—systemic scleroderma	0.00158	0.0211	CbGeAlD
Vandetanib—FLT4—blood vessel—systemic scleroderma	0.00153	0.0205	CbGeAlD
Vandetanib—RIPK2—blood vessel—systemic scleroderma	0.00153	0.0203	CbGeAlD
Vandetanib—SRC—artery—systemic scleroderma	0.00141	0.0188	CbGeAlD
Vandetanib—TEK—endothelium—systemic scleroderma	0.00134	0.0178	CbGeAlD
Vandetanib—KDR—artery—systemic scleroderma	0.00129	0.0173	CbGeAlD
Vandetanib—TEK—blood vessel—systemic scleroderma	0.00123	0.0164	CbGeAlD
Vandetanib—PTK6—skin of body—systemic scleroderma	0.00119	0.0158	CbGeAlD
Vandetanib—SRC—endothelium—systemic scleroderma	0.00119	0.0158	CbGeAlD
Vandetanib—SRC—blood vessel—systemic scleroderma	0.0011	0.0146	CbGeAlD
Vandetanib—KDR—endothelium—systemic scleroderma	0.00109	0.0146	CbGeAlD
Vandetanib—TYRO3—connective tissue—systemic scleroderma	0.00102	0.0136	CbGeAlD
Vandetanib—LYN—connective tissue—systemic scleroderma	0.00101	0.0135	CbGeAlD
Vandetanib—Bosutinib—BLK—systemic scleroderma	0.00101	0.183	CrCbGaD
Vandetanib—KDR—blood vessel—systemic scleroderma	0.00101	0.0134	CbGeAlD
Vandetanib—PTK6—digestive system—systemic scleroderma	0.000951	0.0127	CbGeAlD
Vandetanib—TYRO3—skin of body—systemic scleroderma	0.00092	0.0123	CbGeAlD
Vandetanib—PDGFRB—blood vessel—systemic scleroderma	0.000873	0.0116	CbGeAlD
Vandetanib—FLT3—connective tissue—systemic scleroderma	0.000866	0.0115	CbGeAlD
Vandetanib—LTK—lung—systemic scleroderma	0.000829	0.011	CbGeAlD
Vandetanib—PTK6—lung—systemic scleroderma	0.000794	0.0106	CbGeAlD
Vandetanib—RIPK2—connective tissue—systemic scleroderma	0.000782	0.0104	CbGeAlD
Vandetanib—STK35—skin of body—systemic scleroderma	0.000766	0.0102	CbGeAlD
Vandetanib—ERBB3—connective tissue—systemic scleroderma	0.000749	0.00998	CbGeAlD
Vandetanib—EPHA5—digestive system—systemic scleroderma	0.000736	0.00981	CbGeAlD
Vandetanib—VEGFA—smooth muscle tissue—systemic scleroderma	0.000714	0.00951	CbGeAlD
Vandetanib—RIPK2—skin of body—systemic scleroderma	0.000707	0.00942	CbGeAlD
Vandetanib—RET—connective tissue—systemic scleroderma	0.000695	0.00926	CbGeAlD
Vandetanib—AXL—connective tissue—systemic scleroderma	0.000692	0.00922	CbGeAlD
Vandetanib—ERBB3—skin of body—systemic scleroderma	0.000676	0.00901	CbGeAlD
Vandetanib—PLK4—lung—systemic scleroderma	0.000654	0.00872	CbGeAlD
Vandetanib—FYN—connective tissue—systemic scleroderma	0.000647	0.00863	CbGeAlD
Vandetanib—AXL—smooth muscle tissue—systemic scleroderma	0.000633	0.00843	CbGeAlD
Vandetanib—TEK—connective tissue—systemic scleroderma	0.000633	0.00843	CbGeAlD
Vandetanib—AXL—skin of body—systemic scleroderma	0.000625	0.00833	CbGeAlD
Vandetanib—BMPR1B—lung—systemic scleroderma	0.000602	0.00802	CbGeAlD
Vandetanib—MAP3K19—lung—systemic scleroderma	0.000602	0.00802	CbGeAlD
Vandetanib—FYN—smooth muscle tissue—systemic scleroderma	0.000592	0.00789	CbGeAlD
Vandetanib—FYN—skin of body—systemic scleroderma	0.000585	0.00779	CbGeAlD
Vandetanib—YES1—connective tissue—systemic scleroderma	0.000584	0.00779	CbGeAlD
Vandetanib—STK35—tendon—systemic scleroderma	0.000583	0.00777	CbGeAlD
Vandetanib—TEK—smooth muscle tissue—systemic scleroderma	0.000579	0.00771	CbGeAlD
Vandetanib—MAP4K5—smooth muscle tissue—systemic scleroderma	0.000579	0.00771	CbGeAlD
Vandetanib—VEGFA—Enalapril—Lisinopril—systemic scleroderma	0.00057	0.209	CbGdCrCtD
Vandetanib—ABL2—tendon—systemic scleroderma	0.000568	0.00758	CbGeAlD
Vandetanib—RIPK2—digestive system—systemic scleroderma	0.000565	0.00753	CbGeAlD
Vandetanib—SRC—connective tissue—systemic scleroderma	0.000562	0.00749	CbGeAlD
Vandetanib—FMO1—digestive system—systemic scleroderma	0.000561	0.00747	CbGeAlD
Vandetanib—EPHB6—skin of body—systemic scleroderma	0.000546	0.00728	CbGeAlD
Vandetanib—ERBB3—digestive system—systemic scleroderma	0.000541	0.00721	CbGeAlD
Vandetanib—RIPK2—tendon—systemic scleroderma	0.000538	0.00717	CbGeAlD
Vandetanib—VEGFA—tendon—systemic scleroderma	0.000536	0.00715	CbGeAlD
Vandetanib—YES1—smooth muscle tissue—systemic scleroderma	0.000535	0.00712	CbGeAlD
Vandetanib—FMO1—tendon—systemic scleroderma	0.000534	0.00711	CbGeAlD
Vandetanib—IRAK4—tendon—systemic scleroderma	0.000525	0.007	CbGeAlD
Vandetanib—FLT3—lung—systemic scleroderma	0.000523	0.00696	CbGeAlD
Vandetanib—KDR—connective tissue—systemic scleroderma	0.000517	0.00689	CbGeAlD
Vandetanib—SRC—smooth muscle tissue—systemic scleroderma	0.000514	0.00685	CbGeAlD
Vandetanib—STK35—lung—systemic scleroderma	0.000512	0.00682	CbGeAlD
Vandetanib—MKNK1—digestive system—systemic scleroderma	0.000508	0.00677	CbGeAlD
Vandetanib—SRC—skin of body—systemic scleroderma	0.000508	0.00677	CbGeAlD
Vandetanib—RET—digestive system—systemic scleroderma	0.000502	0.00669	CbGeAlD
Vandetanib—FGR—digestive system—systemic scleroderma	0.000502	0.00669	CbGeAlD
Vandetanib—ABL2—lung—systemic scleroderma	0.000499	0.00665	CbGeAlD
Vandetanib—EGFR—lung—systemic scleroderma	0.000487	0.00649	CbGeAlD
Vandetanib—FGR—tendon—systemic scleroderma	0.000477	0.00636	CbGeAlD
Vandetanib—RET—tendon—systemic scleroderma	0.000477	0.00636	CbGeAlD
Vandetanib—AXL—tendon—systemic scleroderma	0.000476	0.00634	CbGeAlD
Vandetanib—FLT4—lung—systemic scleroderma	0.000475	0.00632	CbGeAlD
Vandetanib—KDR—smooth muscle tissue—systemic scleroderma	0.000473	0.0063	CbGeAlD
Vandetanib—RIPK2—lung—systemic scleroderma	0.000472	0.00629	CbGeAlD
Vandetanib—VEGFA—lung—systemic scleroderma	0.000471	0.00627	CbGeAlD
Vandetanib—FMO1—lung—systemic scleroderma	0.000468	0.00624	CbGeAlD
Vandetanib—FYN—digestive system—systemic scleroderma	0.000468	0.00623	CbGeAlD
Vandetanib—IRAK4—lung—systemic scleroderma	0.000461	0.00614	CbGeAlD
Vandetanib—SLK—tendon—systemic scleroderma	0.000458	0.0061	CbGeAlD
Vandetanib—ERBB3—lung—systemic scleroderma	0.000452	0.00602	CbGeAlD
Vandetanib—PDGFRB—connective tissue—systemic scleroderma	0.000448	0.00597	CbGeAlD
Vandetanib—FYN—tendon—systemic scleroderma	0.000445	0.00593	CbGeAlD
Vandetanib—MAP4K5—tendon—systemic scleroderma	0.000435	0.0058	CbGeAlD
Vandetanib—TEK—tendon—systemic scleroderma	0.000435	0.0058	CbGeAlD
Vandetanib—MKNK1—lung—systemic scleroderma	0.000424	0.00565	CbGeAlD
Vandetanib—YES1—digestive system—systemic scleroderma	0.000422	0.00562	CbGeAlD
Vandetanib—FGR—lung—systemic scleroderma	0.000419	0.00558	CbGeAlD
Vandetanib—LCK—lung—systemic scleroderma	0.000419	0.00558	CbGeAlD
Vandetanib—STK10—digestive system—systemic scleroderma	0.000418	0.00557	CbGeAlD
Vandetanib—AXL—lung—systemic scleroderma	0.000417	0.00556	CbGeAlD
Vandetanib—EPHB6—tendon—systemic scleroderma	0.000416	0.00554	CbGeAlD
Vandetanib—PDGFRB—smooth muscle tissue—systemic scleroderma	0.000409	0.00546	CbGeAlD
Vandetanib—SRC—digestive system—systemic scleroderma	0.000406	0.00541	CbGeAlD
Vandetanib—FMO3—lung—systemic scleroderma	0.000405	0.00539	CbGeAlD
Vandetanib—PDGFRB—skin of body—systemic scleroderma	0.000404	0.00539	CbGeAlD
Vandetanib—SLK—lung—systemic scleroderma	0.000402	0.00535	CbGeAlD
Vandetanib—YES1—tendon—systemic scleroderma	0.000402	0.00535	CbGeAlD
Vandetanib—ABL1—connective tissue—systemic scleroderma	0.000399	0.00532	CbGeAlD
Vandetanib—STK10—tendon—systemic scleroderma	0.000398	0.0053	CbGeAlD
Vandetanib—FYN—lung—systemic scleroderma	0.000391	0.00521	CbGeAlD
Vandetanib—TEK—lung—systemic scleroderma	0.000382	0.00509	CbGeAlD
Vandetanib—MAP4K5—lung—systemic scleroderma	0.000382	0.00509	CbGeAlD
Vandetanib—KDR—digestive system—systemic scleroderma	0.000373	0.00498	CbGeAlD
Vandetanib—ABL1—smooth muscle tissue—systemic scleroderma	0.000365	0.00486	CbGeAlD
Vandetanib—EPHB6—lung—systemic scleroderma	0.000365	0.00486	CbGeAlD
Vandetanib—ABL1—skin of body—systemic scleroderma	0.00036	0.0048	CbGeAlD
Vandetanib—KDR—tendon—systemic scleroderma	0.000355	0.00474	CbGeAlD
Vandetanib—MAP2K5—tendon—systemic scleroderma	0.000355	0.00474	CbGeAlD
Vandetanib—YES1—lung—systemic scleroderma	0.000352	0.0047	CbGeAlD
Vandetanib—STK10—lung—systemic scleroderma	0.000349	0.00466	CbGeAlD
Vandetanib—SRC—lung—systemic scleroderma	0.000339	0.00452	CbGeAlD
Vandetanib—PDGFRB—digestive system—systemic scleroderma	0.000323	0.00431	CbGeAlD
Vandetanib—MAP2K5—lung—systemic scleroderma	0.000312	0.00416	CbGeAlD
Vandetanib—KDR—lung—systemic scleroderma	0.000312	0.00416	CbGeAlD
Vandetanib—PDGFRB—tendon—systemic scleroderma	0.000308	0.0041	CbGeAlD
Vandetanib—ABL1—digestive system—systemic scleroderma	0.000288	0.00384	CbGeAlD
Vandetanib—ABL1—tendon—systemic scleroderma	0.000274	0.00365	CbGeAlD
Vandetanib—PDGFRB—lung—systemic scleroderma	0.00027	0.0036	CbGeAlD
Vandetanib—ORM1—lung—systemic scleroderma	0.000253	0.00338	CbGeAlD
Vandetanib—ABL1—lung—systemic scleroderma	0.000241	0.00321	CbGeAlD
Vandetanib—ABCC1—tendon—systemic scleroderma	0.000209	0.00278	CbGeAlD
Vandetanib—ABCC1—lung—systemic scleroderma	0.000183	0.00244	CbGeAlD
Vandetanib—ABCG2—lung—systemic scleroderma	0.000152	0.00202	CbGeAlD
Vandetanib—VEGFA—Dexamethasone—Mometasone—systemic scleroderma	0.00014	0.0512	CbGdCrCtD
Vandetanib—VEGFA—Betamethasone—Mometasone—systemic scleroderma	0.00014	0.0512	CbGdCrCtD
Vandetanib—CYP3A4—digestive system—systemic scleroderma	0.000127	0.00169	CbGeAlD
Vandetanib—Mental disorder—Mycophenolate mofetil—systemic scleroderma	0.000108	0.000761	CcSEcCtD
Vandetanib—Skin disorder—Mycophenolic acid—systemic scleroderma	0.000108	0.000759	CcSEcCtD
Vandetanib—Loss of consciousness—Lisinopril—systemic scleroderma	0.000108	0.000758	CcSEcCtD
Vandetanib—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.000108	0.000756	CcSEcCtD
Vandetanib—Cough—Lisinopril—systemic scleroderma	0.000107	0.000753	CcSEcCtD
Vandetanib—Alanine aminotransferase increased—Prednisone—systemic scleroderma	0.000107	0.000751	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000107	0.000749	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.000106	0.000747	CcSEcCtD
Vandetanib—Insomnia—Leflunomide—systemic scleroderma	0.000106	0.000741	CcSEcCtD
Vandetanib—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	0.000105	0.00074	CcSEcCtD
Vandetanib—Paraesthesia—Leflunomide—systemic scleroderma	0.000105	0.000736	CcSEcCtD
Vandetanib—Arthralgia—Lisinopril—systemic scleroderma	0.000105	0.000735	CcSEcCtD
Vandetanib—Chest pain—Lisinopril—systemic scleroderma	0.000105	0.000735	CcSEcCtD
Vandetanib—Anxiety—Lisinopril—systemic scleroderma	0.000104	0.000732	CcSEcCtD
Vandetanib—Dyspnoea—Leflunomide—systemic scleroderma	0.000104	0.000731	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000104	0.00073	CcSEcCtD
Vandetanib—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.000103	0.000727	CcSEcCtD
Vandetanib—Lethargy—Methotrexate—systemic scleroderma	0.000103	0.000726	CcSEcCtD
Vandetanib—Dyspepsia—Leflunomide—systemic scleroderma	0.000103	0.000721	CcSEcCtD
Vandetanib—Pancreatitis—Prednisone—systemic scleroderma	0.000103	0.000721	CcSEcCtD
Vandetanib—Vomiting—Mometasone—systemic scleroderma	0.000102	0.00072	CcSEcCtD
Vandetanib—Dry mouth—Lisinopril—systemic scleroderma	0.000102	0.000718	CcSEcCtD
Vandetanib—Rash—Mometasone—systemic scleroderma	0.000102	0.000714	CcSEcCtD
Vandetanib—Asthenia—Captopril—systemic scleroderma	0.000102	0.000714	CcSEcCtD
Vandetanib—Dermatitis—Mometasone—systemic scleroderma	0.000102	0.000713	CcSEcCtD
Vandetanib—Decreased appetite—Leflunomide—systemic scleroderma	0.000101	0.000712	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000101	0.000712	CcSEcCtD
Vandetanib—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000101	0.00071	CcSEcCtD
Vandetanib—Headache—Mometasone—systemic scleroderma	0.000101	0.000709	CcSEcCtD
Vandetanib—Tremor—Mycophenolate mofetil—systemic scleroderma	0.000101	0.000708	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000101	0.000708	CcSEcCtD
Vandetanib—Insomnia—Mycophenolic acid—systemic scleroderma	0.000101	0.000707	CcSEcCtD
Vandetanib—Fatigue—Leflunomide—systemic scleroderma	0.000101	0.000707	CcSEcCtD
Vandetanib—Oedema—Lisinopril—systemic scleroderma	0.0001	0.000704	CcSEcCtD
Vandetanib—Pruritus—Captopril—systemic scleroderma	0.0001	0.000704	CcSEcCtD
Vandetanib—Paraesthesia—Mycophenolic acid—systemic scleroderma	9.99e-05	0.000702	CcSEcCtD
Vandetanib—Constipation—Leflunomide—systemic scleroderma	9.97e-05	0.000701	CcSEcCtD
Vandetanib—Pain—Leflunomide—systemic scleroderma	9.97e-05	0.000701	CcSEcCtD
Vandetanib—Infection—Lisinopril—systemic scleroderma	9.96e-05	0.0007	CcSEcCtD
Vandetanib—Dyspnoea—Mycophenolic acid—systemic scleroderma	9.92e-05	0.000697	CcSEcCtD
Vandetanib—Thrombocytopenia—Lisinopril—systemic scleroderma	9.81e-05	0.00069	CcSEcCtD
Vandetanib—Dyspepsia—Mycophenolic acid—systemic scleroderma	9.8e-05	0.000688	CcSEcCtD
Vandetanib—Neutropenia—Prednisone—systemic scleroderma	9.79e-05	0.000688	CcSEcCtD
Vandetanib—Abdominal pain—Azathioprine—systemic scleroderma	9.76e-05	0.000686	CcSEcCtD
Vandetanib—Body temperature increased—Azathioprine—systemic scleroderma	9.76e-05	0.000686	CcSEcCtD
Vandetanib—Skin disorder—Lisinopril—systemic scleroderma	9.74e-05	0.000684	CcSEcCtD
Vandetanib—Diarrhoea—Captopril—systemic scleroderma	9.68e-05	0.00068	CcSEcCtD
Vandetanib—Decreased appetite—Mycophenolic acid—systemic scleroderma	9.67e-05	0.00068	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	9.61e-05	0.000675	CcSEcCtD
Vandetanib—Fatigue—Mycophenolic acid—systemic scleroderma	9.59e-05	0.000674	CcSEcCtD
Vandetanib—Nausea—Mometasone—systemic scleroderma	9.57e-05	0.000673	CcSEcCtD
Vandetanib—Gastrointestinal pain—Leflunomide—systemic scleroderma	9.54e-05	0.00067	CcSEcCtD
Vandetanib—Pain—Mycophenolic acid—systemic scleroderma	9.52e-05	0.000669	CcSEcCtD
Vandetanib—Constipation—Mycophenolic acid—systemic scleroderma	9.52e-05	0.000669	CcSEcCtD
Vandetanib—Weight decreased—Prednisone—systemic scleroderma	9.47e-05	0.000665	CcSEcCtD
Vandetanib—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	9.46e-05	0.000665	CcSEcCtD
Vandetanib—Hyperglycaemia—Prednisone—systemic scleroderma	9.44e-05	0.000663	CcSEcCtD
Vandetanib—Cough—Mycophenolate mofetil—systemic scleroderma	9.39e-05	0.00066	CcSEcCtD
Vandetanib—Dizziness—Captopril—systemic scleroderma	9.36e-05	0.000658	CcSEcCtD
Vandetanib—Convulsion—Mycophenolate mofetil—systemic scleroderma	9.32e-05	0.000655	CcSEcCtD
Vandetanib—Depression—Prednisone—systemic scleroderma	9.31e-05	0.000654	CcSEcCtD
Vandetanib—Hypertension—Mycophenolate mofetil—systemic scleroderma	9.29e-05	0.000653	CcSEcCtD
Vandetanib—Abdominal pain—Leflunomide—systemic scleroderma	9.22e-05	0.000648	CcSEcCtD
Vandetanib—Body temperature increased—Leflunomide—systemic scleroderma	9.22e-05	0.000648	CcSEcCtD
Vandetanib—Arthralgia—Mycophenolate mofetil—systemic scleroderma	9.16e-05	0.000644	CcSEcCtD
Vandetanib—Chest pain—Mycophenolate mofetil—systemic scleroderma	9.16e-05	0.000644	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	9.13e-05	0.000642	CcSEcCtD
Vandetanib—Anxiety—Mycophenolate mofetil—systemic scleroderma	9.13e-05	0.000641	CcSEcCtD
Vandetanib—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	9.1e-05	0.000639	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	9.1e-05	0.000639	CcSEcCtD
Vandetanib—Insomnia—Lisinopril—systemic scleroderma	9.07e-05	0.000637	CcSEcCtD
Vandetanib—Paraesthesia—Lisinopril—systemic scleroderma	9e-05	0.000632	CcSEcCtD
Vandetanib—Vomiting—Captopril—systemic scleroderma	9e-05	0.000632	CcSEcCtD
Vandetanib—Dry mouth—Mycophenolate mofetil—systemic scleroderma	8.96e-05	0.00063	CcSEcCtD
Vandetanib—Dyspnoea—Lisinopril—systemic scleroderma	8.94e-05	0.000628	CcSEcCtD
Vandetanib—Rash—Captopril—systemic scleroderma	8.92e-05	0.000627	CcSEcCtD
Vandetanib—Dermatitis—Captopril—systemic scleroderma	8.92e-05	0.000626	CcSEcCtD
Vandetanib—Headache—Captopril—systemic scleroderma	8.87e-05	0.000623	CcSEcCtD
Vandetanib—Dyspepsia—Lisinopril—systemic scleroderma	8.82e-05	0.00062	CcSEcCtD
Vandetanib—Abdominal pain—Mycophenolic acid—systemic scleroderma	8.8e-05	0.000618	CcSEcCtD
Vandetanib—Body temperature increased—Mycophenolic acid—systemic scleroderma	8.8e-05	0.000618	CcSEcCtD
Vandetanib—Oedema—Mycophenolate mofetil—systemic scleroderma	8.78e-05	0.000617	CcSEcCtD
Vandetanib—Infection—Mycophenolate mofetil—systemic scleroderma	8.72e-05	0.000613	CcSEcCtD
Vandetanib—Decreased appetite—Lisinopril—systemic scleroderma	8.71e-05	0.000612	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Lisinopril—systemic scleroderma	8.65e-05	0.000608	CcSEcCtD
Vandetanib—Fatigue—Lisinopril—systemic scleroderma	8.64e-05	0.000607	CcSEcCtD
Vandetanib—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	8.61e-05	0.000605	CcSEcCtD
Vandetanib—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	8.6e-05	0.000604	CcSEcCtD
Vandetanib—Pancreatitis—Methotrexate—systemic scleroderma	8.58e-05	0.000603	CcSEcCtD
Vandetanib—Constipation—Lisinopril—systemic scleroderma	8.57e-05	0.000602	CcSEcCtD
Vandetanib—Pain—Lisinopril—systemic scleroderma	8.57e-05	0.000602	CcSEcCtD
Vandetanib—Skin disorder—Mycophenolate mofetil—systemic scleroderma	8.53e-05	0.000599	CcSEcCtD
Vandetanib—Bradycardia—Prednisone—systemic scleroderma	8.53e-05	0.000599	CcSEcCtD
Vandetanib—Diarrhoea—Azathioprine—systemic scleroderma	8.45e-05	0.000594	CcSEcCtD
Vandetanib—Haemoglobin—Prednisone—systemic scleroderma	8.42e-05	0.000592	CcSEcCtD
Vandetanib—Nausea—Captopril—systemic scleroderma	8.41e-05	0.000591	CcSEcCtD
Vandetanib—Haemorrhage—Prednisone—systemic scleroderma	8.38e-05	0.000589	CcSEcCtD
Vandetanib—Asthenia—Leflunomide—systemic scleroderma	8.37e-05	0.000588	CcSEcCtD
Vandetanib—Pruritus—Leflunomide—systemic scleroderma	8.25e-05	0.00058	CcSEcCtD
Vandetanib—Gastrointestinal pain—Lisinopril—systemic scleroderma	8.2e-05	0.000576	CcSEcCtD
Vandetanib—Dysuria—Methotrexate—systemic scleroderma	8.18e-05	0.000575	CcSEcCtD
Vandetanib—Neutropenia—Methotrexate—systemic scleroderma	8.18e-05	0.000575	CcSEcCtD
Vandetanib—Dizziness—Azathioprine—systemic scleroderma	8.17e-05	0.000574	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Methotrexate—systemic scleroderma	8.13e-05	0.000571	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	8e-05	0.000562	CcSEcCtD
Vandetanib—Photosensitivity reaction—Methotrexate—systemic scleroderma	7.99e-05	0.000561	CcSEcCtD
Vandetanib—Asthenia—Mycophenolic acid—systemic scleroderma	7.98e-05	0.000561	CcSEcCtD
Vandetanib—Diarrhoea—Leflunomide—systemic scleroderma	7.98e-05	0.000561	CcSEcCtD
Vandetanib—Insomnia—Mycophenolate mofetil—systemic scleroderma	7.94e-05	0.000558	CcSEcCtD
Vandetanib—Body temperature increased—Lisinopril—systemic scleroderma	7.92e-05	0.000557	CcSEcCtD
Vandetanib—Abdominal pain—Lisinopril—systemic scleroderma	7.92e-05	0.000557	CcSEcCtD
Vandetanib—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	7.89e-05	0.000554	CcSEcCtD
Vandetanib—Pruritus—Mycophenolic acid—systemic scleroderma	7.87e-05	0.000553	CcSEcCtD
Vandetanib—Vomiting—Azathioprine—systemic scleroderma	7.85e-05	0.000552	CcSEcCtD
Vandetanib—Pneumonia—Methotrexate—systemic scleroderma	7.85e-05	0.000551	CcSEcCtD
Vandetanib—Eye disorder—Prednisone—systemic scleroderma	7.83e-05	0.00055	CcSEcCtD
Vandetanib—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	7.83e-05	0.00055	CcSEcCtD
Vandetanib—Infestation NOS—Methotrexate—systemic scleroderma	7.8e-05	0.000548	CcSEcCtD
Vandetanib—Infestation—Methotrexate—systemic scleroderma	7.8e-05	0.000548	CcSEcCtD
Vandetanib—Rash—Azathioprine—systemic scleroderma	7.79e-05	0.000547	CcSEcCtD
Vandetanib—Dermatitis—Azathioprine—systemic scleroderma	7.78e-05	0.000547	CcSEcCtD
Vandetanib—Depression—Methotrexate—systemic scleroderma	7.78e-05	0.000547	CcSEcCtD
Vandetanib—Headache—Azathioprine—systemic scleroderma	7.74e-05	0.000544	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	7.73e-05	0.000543	CcSEcCtD
Vandetanib—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	7.73e-05	0.000543	CcSEcCtD
Vandetanib—Dizziness—Leflunomide—systemic scleroderma	7.71e-05	0.000542	CcSEcCtD
Vandetanib—Renal failure—Methotrexate—systemic scleroderma	7.67e-05	0.000539	CcSEcCtD
Vandetanib—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	7.63e-05	0.000536	CcSEcCtD
Vandetanib—VEGFA—Betamethasone—Prednisone—systemic scleroderma	7.62e-05	0.0279	CbGdCrCtD
Vandetanib—VEGFA—Dexamethasone—Prednisone—systemic scleroderma	7.62e-05	0.0279	CbGdCrCtD
Vandetanib—Diarrhoea—Mycophenolic acid—systemic scleroderma	7.61e-05	0.000535	CcSEcCtD
Vandetanib—Stomatitis—Methotrexate—systemic scleroderma	7.6e-05	0.000534	CcSEcCtD
Vandetanib—Angiopathy—Prednisone—systemic scleroderma	7.6e-05	0.000534	CcSEcCtD
Vandetanib—Conjunctivitis—Methotrexate—systemic scleroderma	7.58e-05	0.000533	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	7.58e-05	0.000533	CcSEcCtD
Vandetanib—Pain—Mycophenolate mofetil—systemic scleroderma	7.51e-05	0.000528	CcSEcCtD
Vandetanib—Constipation—Mycophenolate mofetil—systemic scleroderma	7.51e-05	0.000528	CcSEcCtD
Vandetanib—Arrhythmia—Prednisone—systemic scleroderma	7.48e-05	0.000526	CcSEcCtD
Vandetanib—Haematuria—Methotrexate—systemic scleroderma	7.44e-05	0.000523	CcSEcCtD
Vandetanib—Vomiting—Leflunomide—systemic scleroderma	7.42e-05	0.000521	CcSEcCtD
Vandetanib—Alopecia—Prednisone—systemic scleroderma	7.4e-05	0.00052	CcSEcCtD
Vandetanib—Hepatobiliary disease—Methotrexate—systemic scleroderma	7.38e-05	0.000518	CcSEcCtD
Vandetanib—Dizziness—Mycophenolic acid—systemic scleroderma	7.36e-05	0.000517	CcSEcCtD
Vandetanib—Epistaxis—Methotrexate—systemic scleroderma	7.36e-05	0.000517	CcSEcCtD
Vandetanib—Rash—Leflunomide—systemic scleroderma	7.35e-05	0.000517	CcSEcCtD
Vandetanib—Dermatitis—Leflunomide—systemic scleroderma	7.35e-05	0.000516	CcSEcCtD
Vandetanib—Mental disorder—Prednisone—systemic scleroderma	7.34e-05	0.000516	CcSEcCtD
Vandetanib—Nausea—Azathioprine—systemic scleroderma	7.34e-05	0.000516	CcSEcCtD
Vandetanib—Headache—Leflunomide—systemic scleroderma	7.31e-05	0.000513	CcSEcCtD
Vandetanib—Malnutrition—Prednisone—systemic scleroderma	7.29e-05	0.000513	CcSEcCtD
Vandetanib—Asthenia—Lisinopril—systemic scleroderma	7.19e-05	0.000505	CcSEcCtD
Vandetanib—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	7.18e-05	0.000505	CcSEcCtD
Vandetanib—Pruritus—Lisinopril—systemic scleroderma	7.09e-05	0.000498	CcSEcCtD
Vandetanib—Vomiting—Mycophenolic acid—systemic scleroderma	7.08e-05	0.000497	CcSEcCtD
Vandetanib—Haemoglobin—Methotrexate—systemic scleroderma	7.04e-05	0.000495	CcSEcCtD
Vandetanib—Rash—Mycophenolic acid—systemic scleroderma	7.02e-05	0.000493	CcSEcCtD
Vandetanib—Dermatitis—Mycophenolic acid—systemic scleroderma	7.01e-05	0.000493	CcSEcCtD
Vandetanib—Haemorrhage—Methotrexate—systemic scleroderma	7e-05	0.000492	CcSEcCtD
Vandetanib—Headache—Mycophenolic acid—systemic scleroderma	6.97e-05	0.00049	CcSEcCtD
Vandetanib—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	6.94e-05	0.000488	CcSEcCtD
Vandetanib—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	6.94e-05	0.000488	CcSEcCtD
Vandetanib—Nausea—Leflunomide—systemic scleroderma	6.93e-05	0.000487	CcSEcCtD
Vandetanib—Urinary tract disorder—Methotrexate—systemic scleroderma	6.92e-05	0.000486	CcSEcCtD
Vandetanib—Vision blurred—Prednisone—systemic scleroderma	6.87e-05	0.000483	CcSEcCtD
Vandetanib—Urethral disorder—Methotrexate—systemic scleroderma	6.86e-05	0.000482	CcSEcCtD
Vandetanib—Diarrhoea—Lisinopril—systemic scleroderma	6.86e-05	0.000482	CcSEcCtD
Vandetanib—Visual impairment—Methotrexate—systemic scleroderma	6.75e-05	0.000474	CcSEcCtD
Vandetanib—Dizziness—Lisinopril—systemic scleroderma	6.63e-05	0.000466	CcSEcCtD
Vandetanib—Erythema multiforme—Methotrexate—systemic scleroderma	6.62e-05	0.000465	CcSEcCtD
Vandetanib—Nausea—Mycophenolic acid—systemic scleroderma	6.61e-05	0.000464	CcSEcCtD
Vandetanib—Eye disorder—Methotrexate—systemic scleroderma	6.54e-05	0.00046	CcSEcCtD
Vandetanib—Cardiac disorder—Methotrexate—systemic scleroderma	6.5e-05	0.000457	CcSEcCtD
Vandetanib—Loss of consciousness—Prednisone—systemic scleroderma	6.41e-05	0.00045	CcSEcCtD
Vandetanib—Vomiting—Lisinopril—systemic scleroderma	6.37e-05	0.000448	CcSEcCtD
Vandetanib—Angiopathy—Methotrexate—systemic scleroderma	6.35e-05	0.000446	CcSEcCtD
Vandetanib—Rash—Lisinopril—systemic scleroderma	6.32e-05	0.000444	CcSEcCtD
Vandetanib—Convulsion—Prednisone—systemic scleroderma	6.32e-05	0.000444	CcSEcCtD
Vandetanib—Dermatitis—Lisinopril—systemic scleroderma	6.31e-05	0.000444	CcSEcCtD
Vandetanib—Mediastinal disorder—Methotrexate—systemic scleroderma	6.31e-05	0.000443	CcSEcCtD
Vandetanib—Asthenia—Mycophenolate mofetil—systemic scleroderma	6.3e-05	0.000443	CcSEcCtD
Vandetanib—Hypertension—Prednisone—systemic scleroderma	6.3e-05	0.000442	CcSEcCtD
Vandetanib—Headache—Lisinopril—systemic scleroderma	6.28e-05	0.000441	CcSEcCtD
Vandetanib—Pruritus—Mycophenolate mofetil—systemic scleroderma	6.21e-05	0.000437	CcSEcCtD
Vandetanib—Arthralgia—Prednisone—systemic scleroderma	6.21e-05	0.000436	CcSEcCtD
Vandetanib—Anxiety—Prednisone—systemic scleroderma	6.19e-05	0.000435	CcSEcCtD
Vandetanib—Alopecia—Methotrexate—systemic scleroderma	6.19e-05	0.000435	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	6.17e-05	0.000433	CcSEcCtD
Vandetanib—Mental disorder—Methotrexate—systemic scleroderma	6.13e-05	0.000431	CcSEcCtD
Vandetanib—Malnutrition—Methotrexate—systemic scleroderma	6.1e-05	0.000428	CcSEcCtD
Vandetanib—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	6.01e-05	0.000422	CcSEcCtD
Vandetanib—Dysgeusia—Methotrexate—systemic scleroderma	5.97e-05	0.000419	CcSEcCtD
Vandetanib—Nausea—Lisinopril—systemic scleroderma	5.95e-05	0.000418	CcSEcCtD
Vandetanib—Oedema—Prednisone—systemic scleroderma	5.95e-05	0.000418	CcSEcCtD
Vandetanib—Infection—Prednisone—systemic scleroderma	5.91e-05	0.000416	CcSEcCtD
Vandetanib—Nervous system disorder—Prednisone—systemic scleroderma	5.84e-05	0.00041	CcSEcCtD
Vandetanib—Dizziness—Mycophenolate mofetil—systemic scleroderma	5.81e-05	0.000408	CcSEcCtD
Vandetanib—Skin disorder—Prednisone—systemic scleroderma	5.78e-05	0.000406	CcSEcCtD
Vandetanib—Vision blurred—Methotrexate—systemic scleroderma	5.74e-05	0.000404	CcSEcCtD
Vandetanib—Vomiting—Mycophenolate mofetil—systemic scleroderma	5.58e-05	0.000392	CcSEcCtD
Vandetanib—Rash—Mycophenolate mofetil—systemic scleroderma	5.54e-05	0.000389	CcSEcCtD
Vandetanib—Dermatitis—Mycophenolate mofetil—systemic scleroderma	5.53e-05	0.000389	CcSEcCtD
Vandetanib—Headache—Mycophenolate mofetil—systemic scleroderma	5.5e-05	0.000387	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Prednisone—systemic scleroderma	5.42e-05	0.000381	CcSEcCtD
Vandetanib—Insomnia—Prednisone—systemic scleroderma	5.38e-05	0.000378	CcSEcCtD
Vandetanib—Paraesthesia—Prednisone—systemic scleroderma	5.35e-05	0.000376	CcSEcCtD
Vandetanib—Cough—Methotrexate—systemic scleroderma	5.32e-05	0.000374	CcSEcCtD
Vandetanib—Convulsion—Methotrexate—systemic scleroderma	5.28e-05	0.000371	CcSEcCtD
Vandetanib—Dyspepsia—Prednisone—systemic scleroderma	5.24e-05	0.000368	CcSEcCtD
Vandetanib—Nausea—Mycophenolate mofetil—systemic scleroderma	5.22e-05	0.000367	CcSEcCtD
Vandetanib—Chest pain—Methotrexate—systemic scleroderma	5.19e-05	0.000365	CcSEcCtD
Vandetanib—Arthralgia—Methotrexate—systemic scleroderma	5.19e-05	0.000365	CcSEcCtD
Vandetanib—Decreased appetite—Prednisone—systemic scleroderma	5.17e-05	0.000364	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	5.15e-05	0.000362	CcSEcCtD
Vandetanib—Fatigue—Prednisone—systemic scleroderma	5.13e-05	0.000361	CcSEcCtD
Vandetanib—Constipation—Prednisone—systemic scleroderma	5.09e-05	0.000358	CcSEcCtD
Vandetanib—Infection—Methotrexate—systemic scleroderma	4.94e-05	0.000347	CcSEcCtD
Vandetanib—Nervous system disorder—Methotrexate—systemic scleroderma	4.88e-05	0.000343	CcSEcCtD
Vandetanib—Thrombocytopenia—Methotrexate—systemic scleroderma	4.87e-05	0.000342	CcSEcCtD
Vandetanib—Gastrointestinal pain—Prednisone—systemic scleroderma	4.87e-05	0.000342	CcSEcCtD
Vandetanib—Skin disorder—Methotrexate—systemic scleroderma	4.83e-05	0.00034	CcSEcCtD
Vandetanib—Abdominal pain—Prednisone—systemic scleroderma	4.71e-05	0.000331	CcSEcCtD
Vandetanib—Body temperature increased—Prednisone—systemic scleroderma	4.71e-05	0.000331	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	4.53e-05	0.000318	CcSEcCtD
Vandetanib—Insomnia—Methotrexate—systemic scleroderma	4.5e-05	0.000316	CcSEcCtD
Vandetanib—Paraesthesia—Methotrexate—systemic scleroderma	4.47e-05	0.000314	CcSEcCtD
Vandetanib—Dyspnoea—Methotrexate—systemic scleroderma	4.44e-05	0.000312	CcSEcCtD
Vandetanib—Dyspepsia—Methotrexate—systemic scleroderma	4.38e-05	0.000308	CcSEcCtD
Vandetanib—Decreased appetite—Methotrexate—systemic scleroderma	4.32e-05	0.000304	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Methotrexate—systemic scleroderma	4.29e-05	0.000302	CcSEcCtD
Vandetanib—Fatigue—Methotrexate—systemic scleroderma	4.29e-05	0.000301	CcSEcCtD
Vandetanib—Asthenia—Prednisone—systemic scleroderma	4.27e-05	0.0003	CcSEcCtD
Vandetanib—Pain—Methotrexate—systemic scleroderma	4.25e-05	0.000299	CcSEcCtD
Vandetanib—Pruritus—Prednisone—systemic scleroderma	4.21e-05	0.000296	CcSEcCtD
Vandetanib—Diarrhoea—Prednisone—systemic scleroderma	4.07e-05	0.000286	CcSEcCtD
Vandetanib—Gastrointestinal pain—Methotrexate—systemic scleroderma	4.07e-05	0.000286	CcSEcCtD
Vandetanib—Dizziness—Prednisone—systemic scleroderma	3.94e-05	0.000277	CcSEcCtD
Vandetanib—Abdominal pain—Methotrexate—systemic scleroderma	3.93e-05	0.000276	CcSEcCtD
Vandetanib—Body temperature increased—Methotrexate—systemic scleroderma	3.93e-05	0.000276	CcSEcCtD
Vandetanib—Vomiting—Prednisone—systemic scleroderma	3.78e-05	0.000266	CcSEcCtD
Vandetanib—Rash—Prednisone—systemic scleroderma	3.75e-05	0.000264	CcSEcCtD
Vandetanib—Dermatitis—Prednisone—systemic scleroderma	3.75e-05	0.000263	CcSEcCtD
Vandetanib—Headache—Prednisone—systemic scleroderma	3.73e-05	0.000262	CcSEcCtD
Vandetanib—Asthenia—Methotrexate—systemic scleroderma	3.57e-05	0.000251	CcSEcCtD
Vandetanib—Nausea—Prednisone—systemic scleroderma	3.54e-05	0.000248	CcSEcCtD
Vandetanib—Pruritus—Methotrexate—systemic scleroderma	3.52e-05	0.000247	CcSEcCtD
Vandetanib—Diarrhoea—Methotrexate—systemic scleroderma	3.4e-05	0.000239	CcSEcCtD
Vandetanib—Dizziness—Methotrexate—systemic scleroderma	3.29e-05	0.000231	CcSEcCtD
Vandetanib—Vomiting—Methotrexate—systemic scleroderma	3.16e-05	0.000222	CcSEcCtD
Vandetanib—Rash—Methotrexate—systemic scleroderma	3.14e-05	0.00022	CcSEcCtD
Vandetanib—Dermatitis—Methotrexate—systemic scleroderma	3.13e-05	0.00022	CcSEcCtD
Vandetanib—Headache—Methotrexate—systemic scleroderma	3.12e-05	0.000219	CcSEcCtD
Vandetanib—Nausea—Methotrexate—systemic scleroderma	2.95e-05	0.000208	CcSEcCtD
Vandetanib—EGFR—Immune System—ITGAM—systemic scleroderma	1.34e-05	0.000105	CbGpPWpGaD
Vandetanib—EGFR—Immune System—CD247—systemic scleroderma	1.34e-05	0.000105	CbGpPWpGaD
Vandetanib—EGFR—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	1.34e-05	0.000105	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—HLA-DQB1—systemic scleroderma	1.33e-05	0.000104	CbGpPWpGaD
Vandetanib—YES1—Immune System—HLA-DQB1—systemic scleroderma	1.32e-05	0.000103	CbGpPWpGaD
Vandetanib—EGFR—Disease—CSK—systemic scleroderma	1.32e-05	0.000103	CbGpPWpGaD
Vandetanib—LCK—Disease—HSPG2—systemic scleroderma	1.32e-05	0.000103	CbGpPWpGaD
Vandetanib—ABCC1—Disease—CD247—systemic scleroderma	1.32e-05	0.000103	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—SMAD7—systemic scleroderma	1.31e-05	0.000102	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—CD40LG—systemic scleroderma	1.3e-05	0.000102	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—CCL2—systemic scleroderma	1.29e-05	0.000101	CbGpPWpGaD
Vandetanib—LCK—Immune System—CD247—systemic scleroderma	1.29e-05	0.000101	CbGpPWpGaD
Vandetanib—LCK—Immune System—IRF8—systemic scleroderma	1.29e-05	0.000101	CbGpPWpGaD
Vandetanib—LCK—Immune System—ITGAM—systemic scleroderma	1.29e-05	0.000101	CbGpPWpGaD
Vandetanib—LCK—Disease—CSK—systemic scleroderma	1.27e-05	9.92e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—SMAD7—systemic scleroderma	1.26e-05	9.86e-05	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—NOS3—systemic scleroderma	1.26e-05	9.85e-05	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—CD40LG—systemic scleroderma	1.26e-05	9.82e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—TNFAIP3—systemic scleroderma	1.26e-05	9.82e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—IL1A—systemic scleroderma	1.26e-05	9.8e-05	CbGpPWpGaD
Vandetanib—LYN—Axon guidance—MMP9—systemic scleroderma	1.25e-05	9.79e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—CD40LG—systemic scleroderma	1.25e-05	9.74e-05	CbGpPWpGaD
Vandetanib—ABL1—Axon guidance—MMP9—systemic scleroderma	1.25e-05	9.74e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—BLK—systemic scleroderma	1.24e-05	9.7e-05	CbGpPWpGaD
Vandetanib—VEGFA—Developmental Biology—MMP9—systemic scleroderma	1.24e-05	9.7e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—CD247—systemic scleroderma	1.24e-05	9.68e-05	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—MMP1—systemic scleroderma	1.24e-05	9.65e-05	CbGpPWpGaD
Vandetanib—FYN—Axon guidance—MMP9—systemic scleroderma	1.23e-05	9.63e-05	CbGpPWpGaD
Vandetanib—LCK—Cytokine Signaling in Immune system—IL1B—systemic scleroderma	1.22e-05	9.56e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—CTLA4—systemic scleroderma	1.22e-05	9.54e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—CSK—systemic scleroderma	1.22e-05	9.51e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—RHOB—systemic scleroderma	1.22e-05	9.5e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—HSPG2—systemic scleroderma	1.21e-05	9.47e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—TNFAIP3—systemic scleroderma	1.21e-05	9.46e-05	CbGpPWpGaD
Vandetanib—SRC—Axon guidance—MMP2—systemic scleroderma	1.21e-05	9.45e-05	CbGpPWpGaD
Vandetanib—FMO1—Metabolism—NOS3—systemic scleroderma	1.21e-05	9.42e-05	CbGpPWpGaD
Vandetanib—FGR—Hemostasis—TGFB1—systemic scleroderma	1.2e-05	9.38e-05	CbGpPWpGaD
Vandetanib—YES1—Developmental Biology—MMP9—systemic scleroderma	1.2e-05	9.37e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—IRF5—systemic scleroderma	1.2e-05	9.36e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—BLK—systemic scleroderma	1.2e-05	9.35e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—CTLA4—systemic scleroderma	1.2e-05	9.34e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—CD247—systemic scleroderma	1.19e-05	9.33e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—RHOB—systemic scleroderma	1.19e-05	9.3e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—CTLA4—systemic scleroderma	1.19e-05	9.3e-05	CbGpPWpGaD
Vandetanib—LYN—Developmental Biology—MMP2—systemic scleroderma	1.19e-05	9.29e-05	CbGpPWpGaD
Vandetanib—ABL1—Developmental Biology—MMP2—systemic scleroderma	1.18e-05	9.25e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—HLA-DQB1—systemic scleroderma	1.18e-05	9.2e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—CTLA4—systemic scleroderma	1.18e-05	9.2e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—RHOB—systemic scleroderma	1.17e-05	9.16e-05	CbGpPWpGaD
Vandetanib—FYN—Developmental Biology—MMP2—systemic scleroderma	1.17e-05	9.15e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—HSPG2—systemic scleroderma	1.16e-05	9.09e-05	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—NOS3—systemic scleroderma	1.15e-05	9.01e-05	CbGpPWpGaD
Vandetanib—LCK—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	1.15e-05	8.98e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—HSPG2—systemic scleroderma	1.15e-05	8.96e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—IRF8—systemic scleroderma	1.15e-05	8.94e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—ITGAM—systemic scleroderma	1.15e-05	8.94e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—CD247—systemic scleroderma	1.15e-05	8.94e-05	CbGpPWpGaD
Vandetanib—SRC—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	1.14e-05	8.93e-05	CbGpPWpGaD
Vandetanib—KDR—Developmental Biology—TGFB1—systemic scleroderma	1.14e-05	8.89e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—CSK—systemic scleroderma	1.13e-05	8.78e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—HSPG2—systemic scleroderma	1.12e-05	8.77e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	1.12e-05	8.75e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—SMAD7—systemic scleroderma	1.12e-05	8.73e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—CD40LG—systemic scleroderma	1.11e-05	8.69e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CSK—systemic scleroderma	1.11e-05	8.66e-05	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—MMP9—systemic scleroderma	1.11e-05	8.64e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—HSPG2—systemic scleroderma	1.11e-05	8.64e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—MMP1—systemic scleroderma	1.09e-05	8.55e-05	CbGpPWpGaD
Vandetanib—LYN—Hemostasis—NOS3—systemic scleroderma	1.09e-05	8.54e-05	CbGpPWpGaD
Vandetanib—ABL1—Hemostasis—NOS3—systemic scleroderma	1.09e-05	8.5e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CSK—systemic scleroderma	1.09e-05	8.47e-05	CbGpPWpGaD
Vandetanib—FYN—Hemostasis—NOS3—systemic scleroderma	1.08e-05	8.41e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—TNFAIP3—systemic scleroderma	1.07e-05	8.37e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—CCL2—systemic scleroderma	1.07e-05	8.37e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CSK—systemic scleroderma	1.07e-05	8.34e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—HSPG2—systemic scleroderma	1.07e-05	8.33e-05	CbGpPWpGaD
Vandetanib—EGFR—Axon guidance—MMP9—systemic scleroderma	1.07e-05	8.32e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—BLK—systemic scleroderma	1.06e-05	8.27e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—CD247—systemic scleroderma	1.06e-05	8.26e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—EDN1—systemic scleroderma	1.05e-05	8.23e-05	CbGpPWpGaD
Vandetanib—VEGFA—Developmental Biology—TGFB1—systemic scleroderma	1.02e-05	7.99e-05	CbGpPWpGaD
Vandetanib—SRC—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	1.02e-05	7.95e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—CTLA4—systemic scleroderma	1.02e-05	7.94e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—RHOB—systemic scleroderma	1.01e-05	7.91e-05	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—MMP2—systemic scleroderma	1.01e-05	7.9e-05	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—MMP9—systemic scleroderma	1.01e-05	7.9e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—HLA-DQB1—systemic scleroderma	1.01e-05	7.86e-05	CbGpPWpGaD
Vandetanib—VEGFA—Hemostasis—TGFB1—systemic scleroderma	1e-05	7.84e-05	CbGpPWpGaD
Vandetanib—YES1—Developmental Biology—TGFB1—systemic scleroderma	9.89e-06	7.72e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—HLA-DQB1—systemic scleroderma	9.85e-06	7.69e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—CTLA4—systemic scleroderma	9.81e-06	7.66e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—HLA-DQB1—systemic scleroderma	9.81e-06	7.66e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—RHOB—systemic scleroderma	9.77e-06	7.63e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—HLA-DQB1—systemic scleroderma	9.7e-06	7.57e-05	CbGpPWpGaD
Vandetanib—YES1—Hemostasis—TGFB1—systemic scleroderma	9.7e-06	7.57e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—EDN1—systemic scleroderma	9.65e-06	7.53e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—HSPG2—systemic scleroderma	9.56e-06	7.46e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—NOS3—systemic scleroderma	9.56e-06	7.46e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—IL1A—systemic scleroderma	9.56e-06	7.46e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—CD40LG—systemic scleroderma	9.5e-06	7.42e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—EDN1—systemic scleroderma	9.4e-06	7.34e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—IL1A—systemic scleroderma	9.36e-06	7.31e-05	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—IL1B—systemic scleroderma	9.35e-06	7.3e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—IL1A—systemic scleroderma	9.32e-06	7.27e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—CD40LG—systemic scleroderma	9.31e-06	7.26e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—EDN1—systemic scleroderma	9.3e-06	7.26e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—CD40LG—systemic scleroderma	9.26e-06	7.23e-05	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—MMP9—systemic scleroderma	9.26e-06	7.23e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CSK—systemic scleroderma	9.23e-06	7.21e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—HSPG2—systemic scleroderma	9.21e-06	7.19e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—IL1A—systemic scleroderma	9.21e-06	7.19e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—CTGF—systemic scleroderma	9.19e-06	7.18e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—CD40LG—systemic scleroderma	9.16e-06	7.15e-05	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—TGFB1—systemic scleroderma	9.12e-06	7.12e-05	CbGpPWpGaD
Vandetanib—SRC—Axon guidance—MMP9—systemic scleroderma	9.1e-06	7.1e-05	CbGpPWpGaD
Vandetanib—MKNK1—Disease—TGFB1—systemic scleroderma	9.03e-06	7.05e-05	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—NOS3—systemic scleroderma	8.97e-06	7e-05	CbGpPWpGaD
Vandetanib—LYN—Developmental Biology—MMP9—systemic scleroderma	8.95e-06	6.98e-05	CbGpPWpGaD
Vandetanib—ABL1—Developmental Biology—MMP9—systemic scleroderma	8.9e-06	6.95e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CSK—systemic scleroderma	8.9e-06	6.95e-05	CbGpPWpGaD
Vandetanib—FYN—Developmental Biology—MMP9—systemic scleroderma	8.81e-06	6.87e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—EDN1—systemic scleroderma	8.76e-06	6.84e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—CTLA4—systemic scleroderma	8.68e-06	6.78e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—RHOB—systemic scleroderma	8.65e-06	6.75e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—MMP2—systemic scleroderma	8.64e-06	6.74e-05	CbGpPWpGaD
Vandetanib—FMO3—Metabolism—NOS3—systemic scleroderma	8.62e-06	6.73e-05	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—IL1B—systemic scleroderma	8.46e-06	6.6e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—EDN1—systemic scleroderma	8.45e-06	6.6e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—HLA-DQB1—systemic scleroderma	8.38e-06	6.54e-05	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—TGFB1—systemic scleroderma	8.34e-06	6.51e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—EDN1—systemic scleroderma	8.16e-06	6.37e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—HSPG2—systemic scleroderma	8.16e-06	6.37e-05	CbGpPWpGaD
Vandetanib—BLK—Immune System—IL1B—systemic scleroderma	8.14e-06	6.35e-05	CbGpPWpGaD
Vandetanib—FGR—Immune System—IL1B—systemic scleroderma	8.11e-06	6.33e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—NOS3—systemic scleroderma	8.09e-06	6.32e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—CTGF—systemic scleroderma	8.09e-06	6.32e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—HLA-DQB1—systemic scleroderma	8.08e-06	6.3e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IL1A—systemic scleroderma	7.96e-06	6.21e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—NOS3—systemic scleroderma	7.94e-06	6.2e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—CD40LG—systemic scleroderma	7.91e-06	6.18e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CSK—systemic scleroderma	7.88e-06	6.15e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—MMP9—systemic scleroderma	7.67e-06	5.99e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—IL1A—systemic scleroderma	7.67e-06	5.99e-05	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—TGFB1—systemic scleroderma	7.63e-06	5.96e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—CD40LG—systemic scleroderma	7.63e-06	5.95e-05	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—MMP9—systemic scleroderma	7.61e-06	5.94e-05	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—IL1B—systemic scleroderma	7.46e-06	5.82e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—MMP1—systemic scleroderma	7.39e-06	5.77e-05	CbGpPWpGaD
Vandetanib—LYN—Developmental Biology—TGFB1—systemic scleroderma	7.37e-06	5.76e-05	CbGpPWpGaD
Vandetanib—ABL1—Developmental Biology—TGFB1—systemic scleroderma	7.34e-06	5.73e-05	CbGpPWpGaD
Vandetanib—FYN—Developmental Biology—TGFB1—systemic scleroderma	7.26e-06	5.67e-05	CbGpPWpGaD
Vandetanib—LYN—Hemostasis—TGFB1—systemic scleroderma	7.23e-06	5.65e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—CCL2—systemic scleroderma	7.21e-06	5.63e-05	CbGpPWpGaD
Vandetanib—ABL1—Hemostasis—TGFB1—systemic scleroderma	7.2e-06	5.62e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—HLA-DQB1—systemic scleroderma	7.15e-06	5.58e-05	CbGpPWpGaD
Vandetanib—FYN—Hemostasis—TGFB1—systemic scleroderma	7.12e-06	5.56e-05	CbGpPWpGaD
Vandetanib—ALB—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	6.88e-06	5.37e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL1A—systemic scleroderma	6.79e-06	5.3e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—CD40LG—systemic scleroderma	6.75e-06	5.27e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—CCL2—systemic scleroderma	6.59e-06	5.15e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—HSPG2—systemic scleroderma	6.59e-06	5.14e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—IL1B—systemic scleroderma	6.55e-06	5.11e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—MMP9—systemic scleroderma	6.49e-06	5.07e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—CCL2—systemic scleroderma	6.43e-06	5.02e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—NOS3—systemic scleroderma	6.43e-06	5.02e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—CCL2—systemic scleroderma	6.36e-06	4.96e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—TGFB1—systemic scleroderma	6.32e-06	4.94e-05	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—TGFB1—systemic scleroderma	6.27e-06	4.9e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—EDN1—systemic scleroderma	6.22e-06	4.85e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—EDN1—systemic scleroderma	6.09e-06	4.75e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—EDN1—systemic scleroderma	5.99e-06	4.68e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—CCL2—systemic scleroderma	5.99e-06	4.68e-05	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—TGFB1—systemic scleroderma	5.93e-06	4.63e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—NOS3—systemic scleroderma	5.88e-06	4.59e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—CCL2—systemic scleroderma	5.78e-06	4.51e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—NOS3—systemic scleroderma	5.73e-06	4.47e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—NOS3—systemic scleroderma	5.67e-06	4.42e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—CCL2—systemic scleroderma	5.58e-06	4.36e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—NOS3—systemic scleroderma	5.41e-06	4.22e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—NOS3—systemic scleroderma	5.36e-06	4.18e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—TGFB1—systemic scleroderma	5.35e-06	4.18e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—TGFB1—systemic scleroderma	5.35e-06	4.18e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—TGFB1—systemic scleroderma	5.25e-06	4.1e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—NOS3—systemic scleroderma	5.21e-06	4.07e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—EDN1—systemic scleroderma	5.18e-06	4.04e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—MMP9—systemic scleroderma	5.16e-06	4.02e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—NOS3—systemic scleroderma	5.15e-06	4.02e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CTGF—systemic scleroderma	4.99e-06	3.9e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—EDN1—systemic scleroderma	4.99e-06	3.89e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—IL1B—systemic scleroderma	4.99e-06	3.89e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—NOS3—systemic scleroderma	4.97e-06	3.88e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—IL1B—systemic scleroderma	4.88e-06	3.81e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—IL1B—systemic scleroderma	4.86e-06	3.79e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—IL1B—systemic scleroderma	4.81e-06	3.75e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—NOS3—systemic scleroderma	4.78e-06	3.73e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—MMP9—systemic scleroderma	4.72e-06	3.68e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—MMP9—systemic scleroderma	4.6e-06	3.59e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—MMP9—systemic scleroderma	4.55e-06	3.55e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—NOS3—systemic scleroderma	4.5e-06	3.52e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—EDN1—systemic scleroderma	4.42e-06	3.45e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—NOS3—systemic scleroderma	4.34e-06	3.39e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—TGFB1—systemic scleroderma	4.25e-06	3.32e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CCL2—systemic scleroderma	4.25e-06	3.32e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CCL2—systemic scleroderma	4.16e-06	3.25e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IL1B—systemic scleroderma	4.15e-06	3.24e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—MMP9—systemic scleroderma	4.13e-06	3.22e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CCL2—systemic scleroderma	4.1e-06	3.2e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—NOS3—systemic scleroderma	4e-06	3.12e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—IL1B—systemic scleroderma	4e-06	3.12e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—MMP9—systemic scleroderma	3.99e-06	3.11e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—TGFB1—systemic scleroderma	3.89e-06	3.03e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—NOS3—systemic scleroderma	3.84e-06	3e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—NOS3—systemic scleroderma	3.79e-06	2.96e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—TGFB1—systemic scleroderma	3.79e-06	2.96e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—TGFB1—systemic scleroderma	3.75e-06	2.92e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—NOS3—systemic scleroderma	3.71e-06	2.89e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—NOS3—systemic scleroderma	3.65e-06	2.85e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—TGFB1—systemic scleroderma	3.58e-06	2.79e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—HSPG2—systemic scleroderma	3.56e-06	2.78e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—TGFB1—systemic scleroderma	3.54e-06	2.77e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL1B—systemic scleroderma	3.54e-06	2.76e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CCL2—systemic scleroderma	3.54e-06	2.76e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—NOS3—systemic scleroderma	3.52e-06	2.75e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—TGFB1—systemic scleroderma	3.45e-06	2.69e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CCL2—systemic scleroderma	3.41e-06	2.66e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TGFB1—systemic scleroderma	3.4e-06	2.66e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TGFB1—systemic scleroderma	3.29e-06	2.57e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—TGFB1—systemic scleroderma	3.16e-06	2.47e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—NOS3—systemic scleroderma	3.15e-06	2.46e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—NOS3—systemic scleroderma	3.04e-06	2.37e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MMP9—systemic scleroderma	3.04e-06	2.37e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CCL2—systemic scleroderma	3.02e-06	2.36e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—TGFB1—systemic scleroderma	2.98e-06	2.32e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MMP9—systemic scleroderma	2.98e-06	2.32e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MMP9—systemic scleroderma	2.93e-06	2.29e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—TGFB1—systemic scleroderma	2.87e-06	2.24e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CTGF—systemic scleroderma	2.69e-06	2.1e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NOS3—systemic scleroderma	2.69e-06	2.1e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—TGFB1—systemic scleroderma	2.54e-06	1.98e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MMP9—systemic scleroderma	2.53e-06	1.98e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TGFB1—systemic scleroderma	2.5e-06	1.95e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TGFB1—systemic scleroderma	2.45e-06	1.91e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MMP9—systemic scleroderma	2.44e-06	1.9e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TGFB1—systemic scleroderma	2.41e-06	1.88e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—NOS3—systemic scleroderma	2.17e-06	1.7e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MMP9—systemic scleroderma	2.16e-06	1.69e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TGFB1—systemic scleroderma	2.09e-06	1.63e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TGFB1—systemic scleroderma	2.01e-06	1.57e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TGFB1—systemic scleroderma	1.78e-06	1.39e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—NOS3—systemic scleroderma	1.17e-06	9.16e-06	CbGpPWpGaD
